Cantor Fitzgerald has revised its earnings projection for United Therapeutics, raising the biotechnology firm’s estimated 2025 earnings to $28.70 per share. The announcement points to growing confidence in the company’s potential for continued expansion.

ADAR1 Capital Management LLC has strengthened its position in KALA BIO, Inc. with a notable 35.7% increase in shareholdings. The firm’s total stake now stands at nearly 299,000 shares valued at $1.7 million, reflecting heightened confidence in KALA BIO’s prospects.

Taikang Asset Management Hong Kong Co Ltd has purchased 2,858 shares in Axon Enterprise, Inc, valued at around $1,503,000, according to a recent SEC filing. This move highlights a growing trend of institutional interest in the biotechnology firm and reflects broader market engagement with Axon’s business potential.

Filmmaker Peter Jackson is turning his passion for New Zealand’s natural history into action by partnering with biotech experts to attempt the revival of the extinct moa bird. His unique collaboration aims to bring back the flightless giant that once roamed his homeland.

A research team has unveiled a novel method for isolating high-purity muscle stem cells from pig tissue, a breakthrough that could enhance the production of cultured meat.

CERo Therapeutics has expanded its patent portfolio with new approvals in the United States, marking a significant milestone in the company’s growth. This strategic move strengthens its position in the biotechnology industry and underscores its commitment to innovation.

Illumina has announced a first-of-its-kind spatial transcriptomics technology, marking a significant advancement in the field. The unveiling positions the company at the forefront of technological innovation.